Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome Coronavirus (Mers-Cov) And Engineered Bispecific Fusions With Inhibitory Peptides

The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.